The Effects of Evolocumab in Patients With Diabetes & Atherosclerotic

Status Completed

Clinical Trial Summary

Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition. The eligible subjects will have 6 visits in 13 to 16 weeks and will have Repatha/placebo 140mg subcutaneous every 4 weeks for 3 times since randomization visit, blood tests will be done in each visit to evaluate the effects of evolocumab upon biocellular markers potentially altered by PCSK9 inhibition in a population of type 2 diabetes patients with microvascular dysfunction. Primary Aims: Determine the ACUTE and SHORT-TERM effects of PCSK9 inhibition with evolocumab on biocellular markers of inflammation, immune mediated thrombosis and rheology. The data from this trial will be used to support a clinical trial to assess the role of PCSK9 inhibition in type 2 diabetes patients with cardiac microvascular dysfunction. Secondary Aims: 1. To define the association between PCSK 9 concentrations and immune-related phenotype. 2. To define the association between Lp(a) concentrations, oxidized phospholipids (OxPL), ApoB, biocellular markers of inflammation, tissue factor and immunothrombosis.

Clinical Trial Description

Multi-center, double-blind, randomized, placebo-controlled, parallel group Phase IV study with two treatment arms: evolocumab SC 420 mg/dL QM or matching placebo. The population will include 40 participants with documented Atherosclerotic Vascular Disease (CAD, Stroke, PAD) and type 2 diabetes who receive treatment with maximal tolerated statin therapy and stable doses of anti-hyperglycemic therapy. Subjects will be followed for 12 weeks during the treatment phase, maintaining the double-blind throughout. Assessments of ACUTE and SHORT-TERM effects of PCSK9 inhibition with evolocumab on biocellular markers of endothelial function will be measured at baseline, Week 2, and Week 12. Safety assessments will be undertaken at each study visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03829046
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 4
Start date	June 3, 2019
Completion date	November 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03239366` - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population	Phase 2
Completed	`NCT04597229` - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus	N/A
Completed	`NCT03623139` - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes	N/A
Active, not recruiting	`NCT04599920` - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)	N/A
Active, not recruiting	`NCT03422471` - Hypoglycemia and Autonomic Nervous System Function- B2	N/A
Completed	`NCT04382521` - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions	N/A
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Recruiting	`NCT03458715` - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin	Phase 4
Terminated	`NCT03278236` - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?	N/A
Completed	`NCT02974504` - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)	Phase 4
Completed	`NCT05053828` - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting	`NCT03659383` - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine	Phase 4
Completed	`NCT03542240` - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome	N/A
Completed	`NCT03657537` - Effects of Ketone Bodies on Cognition in Type 2 Diabetes	Phase 1
Completed	`NCT03979768` - Risk Assessment of Type 2 Diabetes in Pharmacies	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Active, not recruiting	`NCT04994288` - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients	Phase 2/Phase 3
Completed	`NCT03290768` - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)	N/A
Enrolling by invitation	`NCT04088851` - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"	N/A
Completed	`NCT03643783` - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms